Breast Cancer Clinical Trial
Official title:
Randomised Clinical Trial of Acupuncture Plus Standard Care Versus Standard Care for Chemotherapy Induced Peripheral Neuropathy (CIPN)
The purpose of this study is to determine whether the addition of acupuncture to standard treatment reduces the level of chemotherapy induced peripheral neuropathy experienced by patients with breast cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer during or following treatment with neurotoxic chemotherapy.
Chemotherapy Induced Peripheral Neuropathy (CIPN) is a significant clinical challenge for
patients receiving specific chemotherapy regimen (e.g. taxanes and Bortezomib) and
critically, if severe, CIPN can lead to the discontinuation of life prolonging treatment.
CIPN poses a major problem for patient care as standard pharmacological treatments for CIPN
have been found to be commonly ineffective and are often inadequate due to dosing
complexities, delayed analgesic onset and side effects.
A service evaluation of the clinical data secured from using acupuncture to manage CIPN
symptoms over a period of 18 months at The Christie National Health Service (NHS) Foundation
Trust suggests it has the potential to provide an efficacious management tool to be used in
addition to standard medication. This aim of this trial is to formally evaluate a 10 week
course of acupuncture in the management of CIPN of grade 2 or above (symptoms experienced
have a functional impact, graded in accordance with CTCAE v4.03), in patients with breast
cancer, multiple myeloma, gastrointestinal cancer or gynaecological cancer.
This is a randomised, phase II, single-centre, controlled, open label trial . Patients
meeting eligibility criteria will be randomised to receive acupuncture plus standard care
(treatment arm) or standard care alone (control arm). Patients in both arms of the study will
receive standard medication to manage symptoms of CIPN, as determined by a clinician in
accordance with local trust policy. In addition to this, patients randomised to the treatment
arm will receive 40 minute sessions of acupuncture on a weekly basis for 10 weeks. All
patients will be offered acupuncture, to commence off trial at the end of their 10 week study
period.
Outcome measures have been focused on assessing the impact of acupuncture on the patients'
quality of life, symptom burden of CIPN and quantifying any effect size. There will also be a
preliminary health economic evaluation of cost effectiveness. The data will be disseminated
in addition to being used to establish whether a larger, multisite trial to confirm efficacy
across all diagnostic groups, user acceptability and cost effectiveness is appropriate. This
work will facilitate the team validating the study protocol and design as a template for a
multicentre study and confirm user acceptability of the approach through additional
qualitative data collected through focus group work at the completion of study participation.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |